Online obesity clinic achieves clinical trial-level weight loss with lower semaglutide doses

Online obesity clinic achieves clinical trial-level weight loss with lower semaglutide doses

New research being presented at this year's European Congress on Obesity (ECO 2025) has found that patients of an online obesity clinic achieved similar weight loss to that reported in clinical trials – but with less than half the medication.

JAMA Cardiology Letter Highlights Limitations and Risks of Semaglutide

JAMA Cardiology Letter Highlights Limitations and Risks of Semaglutide Michael Keevican Wed, 05/14/2025 - 12:30 Featured Image woman-injection.jpg Summary Limited effectiveness, weight regain, and high prevalence of adverse events are the three key limitations of semaglutide highlighted in a letter published in the Journal of the American Medical Association (JAMA) Cardiology. The letter is published in response to research that found that mor…

New Study Challenges GLP-1 Norms With Strong Results on a Fraction of the Usual Dose - PressReach

In one of the largest and longest real-world obesity studies to date, Embla tracked nearly 2,700 adults over 64 weeks and achieved 16.7% average weight loss using 66% less semaglutide than typical U.S. doses Results presented at the European Congress on Obesity, one of the world’s top scientific meetings on obesity research, validate a personalized dosing model that pairs clinical oversight with structured coaching and tapering With GLP-1s proje…

New study challenges GLP-1 norms with strong results on a fraction of the usual dose

AUSTIN – Embla has announced results from a 64-week real-world study presented at the European Congress on Obesity, tracking nearly 2,700 adults in a digital GLP-1 treatment program. The study found that participants lost an average of 16.7% of their body weight on a mean dose of just 1.08 mg of semaglutide per week, substantially lower than the typical 2.4 mg target used in most U.S. treatment models. Nearly 98% of participants lost at least 5%…

New Study Challenges GLP-1 Norms With Strong Results on a Fraction of the Usual Dose

In one of the largest and longest real-world obesity studies to date, Embla tracked nearly 2,700 adults over 64 weeks and achieved 16.7% average weight loss using 66% less semaglutide than typical U.S. dosesResults presented at the European Congress on…